Skip to main content
Erschienen in: Journal of Neurology 6/2011

01.06.2011 | Original Communication

Structural gray and white matter changes in patients with HIV

verfasst von: Michael Küper, K. Rabe, S. Esser, E. R. Gizewski, I. W. Husstedt, M. Maschke, M. Obermann

Erschienen in: Journal of Neurology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

In this cross-sectional study we used magnetic resonance imaging (MRI)-based voxel based morphometry (VBM) in a sample of HIV positive patients to detect structural gray and white matter changes. Forty-eight HIV positive subjects with (n = 28) or without (n = 20) cognitive deficits (mean age 48.5 ± 9.6 years) and 48 age- and sex-matched HIV negative controls underwent MRI for VBM analyses. Clinical testing in HIV patients included the HIV dementia scale (HDS), Unified Parkinson’s Disease Rating Scale (UPDRS) and the grooved pegboard test. Comparing controls with HIV positive patients with cognitive dysfunction (n = 28) VBM showed gray matter decrease in the anterior cingulate and temporal cortices along with white matter reduction in the midbrain region. These changes were more prominent with increasing cognitive decline, when assigning HIV patients to three cognitive groups (not impaired, mildly impaired, overtly impaired) based on performance in the HIV dementia scale. Regression analysis including all HIV positive patients with available data revealed that prefrontal gray matter atrophy in HIV was associated with longer disease duration (n = 48), while motor dysfunction (n = 48) was associated with basal ganglia gray matter atrophy. Lower CD4 cell count (n = 47) correlated with decrease of occipital gray matter. Our results provide evidence for atrophy of nigro-striatal and fronto-striatal circuits in HIV. This pattern of atrophy is consistent with motor dysfunction and dysexecutive syndrome found in HIV patients with HIV-associated neurocognitive disorder.
Literatur
1.
Zurück zum Zitat Everall IP, Luthert PJ, Lantos PL (1993) Neuronal number and volume alterations in the neocortex of HIV infected individuals. J Neurol Neurosurg Psychiatr 56:481–486CrossRefPubMed Everall IP, Luthert PJ, Lantos PL (1993) Neuronal number and volume alterations in the neocortex of HIV infected individuals. J Neurol Neurosurg Psychiatr 56:481–486CrossRefPubMed
2.
Zurück zum Zitat Fischer CP, Jorgen G, Gundersen H, Pakkenberg B (1999) Preferential loss of large neocortical neurons during HIV infection: a study of the size distribution of neocortical neurons in the human brain. Brain Res 828:119–126CrossRefPubMed Fischer CP, Jorgen G, Gundersen H, Pakkenberg B (1999) Preferential loss of large neocortical neurons during HIV infection: a study of the size distribution of neocortical neurons in the human brain. Brain Res 828:119–126CrossRefPubMed
3.
Zurück zum Zitat Adle-Biassette H, Chrétien F, Wingertsmann L, Héry C, Ereau T, Scaravilli F et al (1999) Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol 25:123–133CrossRefPubMed Adle-Biassette H, Chrétien F, Wingertsmann L, Héry C, Ereau T, Scaravilli F et al (1999) Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol 25:123–133CrossRefPubMed
4.
Zurück zum Zitat Scaravilli F, Bazille C, Gray F (2007) Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol 17:197–208CrossRefPubMed Scaravilli F, Bazille C, Gray F (2007) Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol 17:197–208CrossRefPubMed
5.
Zurück zum Zitat Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T et al (1998) Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch Neurol 55:161–168CrossRefPubMed Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T et al (1998) Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch Neurol 55:161–168CrossRefPubMed
6.
Zurück zum Zitat Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE et al (1993) Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43:2099–2104PubMed Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE et al (1993) Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43:2099–2104PubMed
7.
Zurück zum Zitat Chiang M, Dutton RA, Hayashi KM, Lopez OL, Aizenstein HJ, Toga AW et al (2007) 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage 34:44–60CrossRefPubMed Chiang M, Dutton RA, Hayashi KM, Lopez OL, Aizenstein HJ, Toga AW et al (2007) 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage 34:44–60CrossRefPubMed
8.
Zurück zum Zitat Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ et al (2005) Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 102:15647–15652CrossRefPubMed Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ et al (2005) Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 102:15647–15652CrossRefPubMed
9.
Zurück zum Zitat Cardenas V, Meyerhoff D, Studholme C, Kornak J, Rothlind J, Lampiris H et al (2009) Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 15:1–10CrossRef Cardenas V, Meyerhoff D, Studholme C, Kornak J, Rothlind J, Lampiris H et al (2009) Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 15:1–10CrossRef
10.
Zurück zum Zitat Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A et al (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16:25–32CrossRefPubMed Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A et al (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16:25–32CrossRefPubMed
11.
Zurück zum Zitat Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC et al (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70CrossRefPubMed Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC et al (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70CrossRefPubMed
12.
Zurück zum Zitat Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML et al (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52:56–63CrossRefPubMed Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML et al (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52:56–63CrossRefPubMed
13.
Zurück zum Zitat Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK et al (2004) Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56:416–423CrossRefPubMed Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK et al (2004) Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56:416–423CrossRefPubMed
14.
Zurück zum Zitat Power C, Selnes OA, Grim JA, McArthur JC (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8:273–278CrossRefPubMed Power C, Selnes OA, Grim JA, McArthur JC (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8:273–278CrossRefPubMed
15.
Zurück zum Zitat Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A (2000) Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatr 69:376–380CrossRefPubMed Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A (2000) Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatr 69:376–380CrossRefPubMed
16.
Zurück zum Zitat Cysique LA, Brew BJ (2009) Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 19:169–185CrossRefPubMed Cysique LA, Brew BJ (2009) Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 19:169–185CrossRefPubMed
17.
Zurück zum Zitat Simioni S, Cavassini M, Annoni J, Rimbault Abraham A, Bourquin I, Schiffer V et al (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250PubMed Simioni S, Cavassini M, Annoni J, Rimbault Abraham A, Bourquin I, Schiffer V et al (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250PubMed
18.
Zurück zum Zitat Ashburner J, Friston KJ (2000) Voxel-based morphometry––the methods. Neuroimage 11:805–821CrossRefPubMed Ashburner J, Friston KJ (2000) Voxel-based morphometry––the methods. Neuroimage 11:805–821CrossRefPubMed
19.
Zurück zum Zitat Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14:21–36CrossRefPubMed Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14:21–36CrossRefPubMed
20.
Zurück zum Zitat Obermann M, Küper M, Kastrup O, Yaldizli O, Esser S, Thiermann J et al (2009) Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. J Neurol 256:948–953CrossRefPubMed Obermann M, Küper M, Kastrup O, Yaldizli O, Esser S, Thiermann J et al (2009) Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. J Neurol 256:948–953CrossRefPubMed
21.
Zurück zum Zitat Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289CrossRefPubMed Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289CrossRefPubMed
22.
Zurück zum Zitat Ernst T, Yakupov R, Nakama H, Crocket G, Cole M, Watters M et al (2009) Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol 65:316–325CrossRefPubMed Ernst T, Yakupov R, Nakama H, Crocket G, Cole M, Watters M et al (2009) Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol 65:316–325CrossRefPubMed
23.
Zurück zum Zitat Iudicello JE, Woods SP, Parsons TD, Moran LM, Carey CL, Grant I (2007) Verbal fluency in HIV infection: a meta-analytic review. J Int Neuropsychol Soc 13:183–189CrossRefPubMed Iudicello JE, Woods SP, Parsons TD, Moran LM, Carey CL, Grant I (2007) Verbal fluency in HIV infection: a meta-analytic review. J Int Neuropsychol Soc 13:183–189CrossRefPubMed
24.
Zurück zum Zitat Woods SP, Carey CL, Tröster AI, Grant I (2005) Action (verb) generation in HIV-1 infection. Neuropsychologia 43:1144–1151CrossRefPubMed Woods SP, Carey CL, Tröster AI, Grant I (2005) Action (verb) generation in HIV-1 infection. Neuropsychologia 43:1144–1151CrossRefPubMed
25.
Zurück zum Zitat Mitchell RLC (2010) Linear increases in BOLD response associated with increasing proportion of incongruent trials across time in a colour Stroop task. Exp Brain Res 203:193–204CrossRefPubMed Mitchell RLC (2010) Linear increases in BOLD response associated with increasing proportion of incongruent trials across time in a colour Stroop task. Exp Brain Res 203:193–204CrossRefPubMed
26.
Zurück zum Zitat Chen Y, An H, Zhu H, Stone T, Smith JK, Hall C et al (2009) White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients. Neuroimage 47:1154–1162CrossRefPubMed Chen Y, An H, Zhu H, Stone T, Smith JK, Hall C et al (2009) White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients. Neuroimage 47:1154–1162CrossRefPubMed
27.
Zurück zum Zitat White DA, Taylor MJ, Butters N, Mack C, Salmon DP, Peavy G et al (1997) Memory for verbal information in individuals with HIV-associated dementia complex. HNRC Group. J Clin Exp Neuropsychol 19:357–366CrossRefPubMed White DA, Taylor MJ, Butters N, Mack C, Salmon DP, Peavy G et al (1997) Memory for verbal information in individuals with HIV-associated dementia complex. HNRC Group. J Clin Exp Neuropsychol 19:357–366CrossRefPubMed
28.
Zurück zum Zitat Gongvatana A, Woods SP, Taylor MJ, Vigil O, Grant I (2007) Semantic clustering inefficiency in HIV-associated dementia. J Neuropsychiatry Clin Neurosci 19:36–42CrossRefPubMed Gongvatana A, Woods SP, Taylor MJ, Vigil O, Grant I (2007) Semantic clustering inefficiency in HIV-associated dementia. J Neuropsychiatry Clin Neurosci 19:36–42CrossRefPubMed
29.
Zurück zum Zitat Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14:214–221CrossRefPubMed Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14:214–221CrossRefPubMed
30.
Zurück zum Zitat Kaiser S, Kopka M, Rentrop M, Walther S, Kronmüller K, Olbrich R et al (2010) Maintenance of real objects and their verbal designations in working memory. Neurosci Lett 469:65–69CrossRefPubMed Kaiser S, Kopka M, Rentrop M, Walther S, Kronmüller K, Olbrich R et al (2010) Maintenance of real objects and their verbal designations in working memory. Neurosci Lett 469:65–69CrossRefPubMed
32.
Zurück zum Zitat Thothathiri M, Schwartz MF, Thompson-Schill SL (2010) Selection for position: the role of left ventrolateral prefrontal cortex in sequencing language. Brain Lang 113:28–38CrossRefPubMed Thothathiri M, Schwartz MF, Thompson-Schill SL (2010) Selection for position: the role of left ventrolateral prefrontal cortex in sequencing language. Brain Lang 113:28–38CrossRefPubMed
33.
Zurück zum Zitat Pascal S, Resnick L, Barker WW, Loewenstein D, Yoshii F, Chang JY et al (1991) Metabolic asymmetries in asymptomatic HIV-1 seropositive subjects: relationship to disease onset and MRI findings. J Nucl Med 32:1725–1729PubMed Pascal S, Resnick L, Barker WW, Loewenstein D, Yoshii F, Chang JY et al (1991) Metabolic asymmetries in asymptomatic HIV-1 seropositive subjects: relationship to disease onset and MRI findings. J Nucl Med 32:1725–1729PubMed
34.
Zurück zum Zitat Melrose RJ, Tinaz S, Castelo JMB, Courtney MG, Stern CE (2008) Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res 188:337–347CrossRefPubMed Melrose RJ, Tinaz S, Castelo JMB, Courtney MG, Stern CE (2008) Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res 188:337–347CrossRefPubMed
35.
Zurück zum Zitat Ances BM, Roc AC, Wang J, Korczykowski M, Okawa J, Stern J et al (2006) Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology 66:862–866CrossRefPubMed Ances BM, Roc AC, Wang J, Korczykowski M, Okawa J, Stern J et al (2006) Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology 66:862–866CrossRefPubMed
36.
Zurück zum Zitat Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M (2007) Human immunodeficiency virus type 1 RNA levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 13:210–224CrossRefPubMed Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M (2007) Human immunodeficiency virus type 1 RNA levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 13:210–224CrossRefPubMed
37.
Zurück zum Zitat Kumar AM, Fernandez J, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL et al (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:1–18CrossRef Kumar AM, Fernandez J, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL et al (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:1–18CrossRef
38.
Zurück zum Zitat Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE et al (2009) Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 73:702–708CrossRefPubMed Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE et al (2009) Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 73:702–708CrossRefPubMed
39.
Zurück zum Zitat Banks WA, Robinson SM, Nath A (2005) Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 193:218–227CrossRefPubMed Banks WA, Robinson SM, Nath A (2005) Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 193:218–227CrossRefPubMed
40.
Zurück zum Zitat Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP et al (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342–348CrossRefPubMed Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP et al (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342–348CrossRefPubMed
Metadaten
Titel
Structural gray and white matter changes in patients with HIV
verfasst von
Michael Küper
K. Rabe
S. Esser
E. R. Gizewski
I. W. Husstedt
M. Maschke
M. Obermann
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 6/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5883-y

Weitere Artikel der Ausgabe 6/2011

Journal of Neurology 6/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.